FCCC LOGO Faculty Publications
Tempero MA , Malafa MP , Behrman SW , Benson AB 3rd , Casper ES , Chiorean EG , Chung V , Cohen SJ , Czito B , Engebretson A , Feng M , Hawkins WG , Herman J , Hoffman JP , Ko A , Komanduri S , Koong A , Lowy AM , Ma WW , Merchant NB , Mulvihill SJ , Muscarella P 2nd , Nakakura EK , Obando J , Pitman MB , Reddy S , Sasson AR , Thayer SP , Weekes CD , Wolff RA , Wolpin BM , Burns JL , Freedman-Cass DA
Pancreatic adenocarcinoma, version 2.2014
J Natl Compr Canc Netw. 2014 Aug;12(8) :1083-93
PMID: 25099441   
Back to previous list
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.
1540-1413 Tempero, Margaret A Malafa, Mokenge P Behrman, Stephen W Benson, Al B 3rd Casper, Ephraim S Chiorean, E Gabriela Chung, Vincent Cohen, Steven J Czito, Brian Engebretson, Anitra Feng, Mary Hawkins, William G Herman, Joseph Hoffman, John P Ko, Andrew Komanduri, Srinadh Koong, Albert Lowy, Andrew M Ma, Wen Wee Merchant, Nipun B Mulvihill, Sean J Muscarella, Peter 2nd Nakakura, Eric K Obando, Jorge Pitman, Martha B Reddy, Sushanth Sasson, Aaron R Thayer, Sarah P Weekes, Colin D Wolff, Robert A Wolpin, Brian M Burns, Jennifer L Freedman-Cass, Deborah A Journal Article United States J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.